Core Viewpoint - The Wuxi High-tech Zone has been recognized for its significant achievements in fostering specialized and innovative small and medium-sized enterprises (SMEs), leading the city with a total of 626 recognized enterprises to date [3]. Group 1: Recognition and Achievements - In the 2025 provincial recognition of specialized and innovative SMEs, Wuxi High-tech Zone had 224 enterprises recognized, ranking first in the city, with an additional 107 enterprises passing the review [1]. - A total of 243 new recognitions were added in the 2025 application process, maintaining the highest cumulative recognition in the city [3]. Group 2: Industry Focus - Approximately 80% of the recognized enterprises are concentrated in high-end equipment, IoT, high-end software, integrated circuits, new materials, and new energy sectors [3]. - The average R&D intensity of these enterprises is 7%, and they hold an average of 24 valid authorized patents [3]. Group 3: Support and Development Strategies - The Wuxi High-tech Zone emphasizes the cultivation of quality SMEs through policy support, service provision, and resource guarantees, implementing multiple measures to promote the development of specialized and innovative enterprises [3]. - The zone plans to attract 3,279 technology-based enterprises by enhancing collaboration among departments and improving the monitoring and support system for SMEs [4]. Group 4: Service Optimization - The region is focused on providing comprehensive empowerment services for enterprises, including digital transformation, standard certification, intellectual property, and financing support [5]. - Regular monitoring of the development needs of specialized and innovative enterprises is conducted to address their challenges effectively [5]. Group 5: Resource Allocation - Resources and services are directed towards high-quality specialized and innovative enterprises, including meeting their land and factory needs [6]. - Various activities, such as industry chain matching and overseas expansion events, are organized to promote the integration and growth of enterprises [6]. Group 6: Future Directions - The Wuxi High-tech Zone aims to deepen the integration of technological and industrial innovation, focusing on attracting quality projects and enhancing innovation capabilities [7]. - The goal is to create a robust industrial ecosystem that supports the continuous improvement of specialized and innovative SMEs, facilitating their upgrade to "little giant" and "single champion" enterprises [7].

大连股交中心目前大股东为大连市国有金融资本管理运营有限公司。"大连股交中心的发展，获得了大 连金运公司及旗下担保、租赁、保理等板块丰富的金融资源支持。"王松说。 值得一提的是，目前，大连股交中心部分高管还在大连市引导基金管理有限责任公司任职。以王松为 例，其另一身份是大连引导基金管理公司总经理。大连引导基金管理公司是由大连金运公司出资设立的 大连市政府引导母基金管理机构，采取市场化、专业化方式管理运营。 大连股交中心总经理王松日前在接受中国证券报记者专访时表示，作为大连市唯一合法的区域性股权市 场运营机构，大连股交中心将坚持高标准站位，保持韧性、耐心和定力，以沉下去的功夫做好各项基础 工作，发挥多层次资本市场"塔基"和企业上市"苗圃"作用，扩大特色优势，为优质中小企业提供全方 位、全生命周期的金融服务，聚焦专精特新企业梯度培育，打通资本与实体经济连接通道，助力优质企 业利用资本市场实现高质量发展。 成果丰硕 近日，大连股交中心"专精特新"专板培育层企业康丰科技获准挂牌新三板。这家深耕连续挤压和包覆技 术领域的科技型企业曾三次荣获国家科技进步奖，此次能快速在新三板挂牌、实现在资本市场进阶发 展，正是得益于三四板 ...

大连股交中心总经理王松日前在接受中国证券报记者专访时表示，作为大连市唯一合法的区域性股权市 场运营机构，大连股交中心将坚持高标准站位，保持韧性、耐心和定力，以沉下去的功夫做好各项基础 工作，发挥多层次资本市场"塔基"和企业上市"苗圃"作用，扩大特色优势，为优质中小企业提供全方 位、全生命周期的金融服务，聚焦专精特新企业梯度培育，打通资本与实体经济连接通道，助力优质企 业利用资本市场实现高质量发展。 特色优势显著 大连股交中心目前大股东为大连市国有金融资本管理运营有限公司。"大连股交中心的发展，获得了大 连金运公司及旗下担保、租赁、保理等板块丰富的金融资源支持。"王松说。 值得一提的是，目前，大连股交中心部分高管还在大连市引导基金管理有限责任公司任职。以王松为 例，其另一身份是大连引导基金管理公司总经理。大连引导基金管理公司是由大连金运公司出资设立的 大连市政府引导母基金管理机构，采取市场化、专业化方式管理运营。 在挖掘及走访企业过程中，大连股交中心与大连引导基金管理公司两家兄弟单位往往共同参与，实现资 源共享、优势互补，进一步提升走访实效，找出一批好企业并实现长期赋能。 "大连股交中心与大连引导基金管理公司协 ...

● 本报记者 宋维东 大连股交中心总经理王松日前在接受中国证券报记者专访时表示，作为大连市唯一合法的区域性股权市 场运营机构，大连股交中心将坚持高标准站位，保持韧性、耐心和定力，以沉下去的功夫做好各项基础 工作，发挥多层次资本市场"塔基"和企业上市"苗圃"作用，扩大特色优势，为优质中小企业提供全方 位、全生命周期的金融服务，聚焦专精特新企业梯度培育，打通资本与实体经济连接通道，助力优质企 业利用资本市场实现高质量发展。 成果丰硕 近日，大连股交中心"专精特新"专板培育层企业康丰科技获准挂牌新三板。这家深耕连续挤压和包覆技 术领域的科技型企业曾三次荣获国家科技进步奖，此次能快速在新三板挂牌、实现在资本市场进阶发 展，正是得益于三四板"绿色通道"机制的全程协助。 "为破解企业挂牌周期长、流程衔接难等痛点，2024年大连股交中心与全国股转公司签署《监管合作备 忘录》，正式开通三四板'绿色通道'，为以专精特新企业为代表的拟挂牌、拟上市企业搭建对接资本市 场的直达通道。"王松说。 康丰科技的快速挂牌，正是大连股交中心高效链接全国性资本市场资源、助力区域优质企业加速对接新 三板的有益实践，也是精准服务中小企业的经典案例。 ...

Core Viewpoint - Anhui Xiaoxiao Technology Co., Ltd. is in the process of updating its listing application review on the Beijing Stock Exchange, addressing inquiries related to operational performance stability, revenue authenticity verification, and cash and inventory verification [1][2]. Group 1: Operational Performance Stability - The company attributes current performance fluctuations to a combination of industry transformation and structural adjustments within the company, expecting continued improvement in performance due to deepening cooperation with core customers, increasing orders from new clients, and the ramp-up of new business into mass production [1] - The company anticipates that its performance will maintain the upward trend observed since the third quarter [1]. Group 2: Revenue Authenticity Verification - The company asserts that the trends in its overseas business performance are reasonable, with the structure of overseas sales revenue and costs showing logical changes during the reporting period [1] - Variations in regional concentration, sales and settlement cycles, major customers, and sales amounts are deemed reasonable, with matching customs declaration data, export tax rebate data, foreign exchange gains and losses, logistics records, and shipping acceptance documents [1]. Group 3: Cash and Inventory Verification - The company indicates that changes in cash funds align with variations in operating income and accounts receivable/payable, as well as investment financing situations [2] - The average deposit interest rate during the reporting period is within a reasonable range, with interest income matching the scale of bank deposits, and no anomalies in the relationship between bank deposits and interest income [2]. - The company maintains appropriate inventory levels and has accounted for inventory impairment in accordance with accounting standards, with no signs of asset impairment or idleness in production equipment [2]. Group 4: Company Overview - The company is primarily engaged in the research, development, production, and sales of precision components for automotive transmission and power systems, adhering to the philosophy that "quality is the root of enterprise survival, and innovation is the path to enterprise development" [3].

Core Viewpoint - Antai Technology (000969.SZ) is enhancing its competitive position in the welding materials sector through strategic investment and structural adjustments during the 14th Five-Year Plan period [1] Group 1: Company Performance and Strategy - Antai San Ying is focusing on market demand to continuously adjust its industrial structure and upgrade its products, leading to steady improvement in operational performance [1] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small and medium-sized enterprise in Tianjin, as well as a "Cheetah Enterprise" [1] Group 2: Investment and Ownership Changes - The company plans to invest an additional 20 million RMB in Antai San Ying using its own funds, with 17,915,330 RMB allocated to registered capital and the remainder to capital reserves [1] - Following this capital increase, the company's ownership stake in Antai San Ying will rise from 50.588% to 59.1898%, maintaining Antai San Ying as a controlled subsidiary whose financial statements will continue to be included in the company's consolidated financial statements [1]

Core Viewpoint - Haosen Pharmaceutical has been recognized as a national-level "specialized, refined, and innovative" small giant enterprise, which enhances its brand recognition and industry influence, positively impacting its overall development [1][2]. Group 1: Recognition and Impact - The company was previously recognized as a specialized and innovative small enterprise in Zhejiang Province in 2021 and has now achieved national-level recognition [1]. - This recognition by the Ministry of Industry and Information Technology acknowledges the company's technological level, innovation capability, manufacturing quality, and overall strength [1]. Group 2: Research and Development - In the first three quarters of 2025, the company invested a total of 28.1661 million yuan in research and development, representing a year-on-year increase of 57.96% [1]. - The company is pursuing a multi-channel and diversified approach to convert research outcomes into market value through collaborations with research enterprises and universities [1]. Group 3: Product Pipeline - As of June 30, 2025, the company has 17 products under research, including APIs, intermediates, and formulations, targeting various therapeutic areas such as antiviral, antidepressant, lipid-lowering, non-steroidal anti-inflammatory, anti-rheumatic, and anti-ulcer medications [1]. Group 4: Corporate Mission and Strategy - The company is committed to continuously researching, producing, and promoting excellent pharmaceutical products and services to enhance people's quality of life [2]. - It focuses on the research, production, and sales of chemical pharmaceutical raw materials, intermediates, and formulations, aiming for specialized development and increased R&D investment to strengthen its core competitiveness [2].

Core Viewpoint - Haisen Pharmaceutical (001367.SZ) has been recognized as a "Little Giant" enterprise in the seventh batch of specialized and innovative small and medium-sized enterprises by the Ministry of Industry and Information Technology of China [1] Group 1 - Haisen Pharmaceutical has successfully passed the certification for the seventh batch of specialized and innovative "Little Giant" enterprises [1] - The recognition is part of a broader initiative by the Ministry of Industry and Information Technology to identify and support innovative companies [1]

Group 1 - The core point of the article is that Haisen Pharmaceutical has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise by the Ministry of Industry and Information Technology, which enhances the company's brand recognition and industry influence [1] - Haisen Pharmaceutical was previously recognized as a specialized and innovative small enterprise in Zhejiang Province in 2021, indicating a consistent track record of innovation and capability [1] - The company's revenue composition for the first half of 2025 is entirely from the pharmaceutical manufacturing industry, indicating a focused business model [1] Group 2 - As of the report, Haisen Pharmaceutical has a market capitalization of 3.3 billion yuan [2]

Group 1 - Shenzhen leads China with a total of 1,333 "specialized, refined, distinctive, and innovative" (专精特新) "little giant" enterprises, surpassing Beijing (1,210) and Shanghai (1,032) [2][3] - The growth of "little giant" enterprises in Shenzhen reflects a focus on key segments of the industrial chain, mastery of core technologies, and high market share, indicating a high level of development in China's manufacturing sector [3] - Shenzhen's proportion of newly added "little giants" has increased from 6.3% in 2022 to 8.4% in 2023, and is projected to reach 9.8% in 2024 and 9.9% in 2025, maintaining the top position in the country for three consecutive years [4] Group 2 - Notable "little giants" include Jieput's MOPA pulsed fiber laser, which holds over 70% of the domestic market and ranks first globally, and Guangyue Technology, which has developed world-leading high-power transmission cable series [4] - Shenzhen's "little giants" exhibit an average R&D intensity of 7.63%, with annual R&D expenditure averaging 33.39 million yuan, surpassing the national average for similar enterprises [4] - The city has established a comprehensive nurturing system for enterprises, with plans to support "gazelle" and "unicorn" companies through a structured service system aimed at fostering innovation and collaboration within the electronic manufacturing ecosystem [5]